<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK476444" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK476444/" /><meta name="ncbi_pagename" content="INSR-Related Severe Syndromic Insulin Resistance - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>INSR-Related Severe Syndromic Insulin Resistance - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="INSR-Related Severe Syndromic Insulin Resistance" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/01/25" /><meta name="citation_author" content="Shani Ben Harouch" /><meta name="citation_author" content="Aharon Klar" /><meta name="citation_author" content="Tzipora C Falik Zaccai" /><meta name="citation_pmid" content="29369573" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK476444/" /><meta name="citation_keywords" content="Rabson-Mendenhall Syndrome" /><meta name="citation_keywords" content="Donohue Syndrome" /><meta name="citation_keywords" content="Insulin receptor" /><meta name="citation_keywords" content="INSR" /><meta name="citation_keywords" content="INSR-Related Severe Syndromic Insulin Resistance" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="INSR-Related Severe Syndromic Insulin Resistance" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Shani Ben Harouch" /><meta name="DC.Contributor" content="Aharon Klar" /><meta name="DC.Contributor" content="Tzipora C Falik Zaccai" /><meta name="DC.Date" content="2018/01/25" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK476444/" /><meta name="description" content="INSR-related severe syndromic insulin resistance comprises a phenotypic spectrum that is a continuum from the severe phenotype Donohue syndrome (DS) (also known as leprechaunism) to the milder phenotype Rabson-Mendenhall syndrome (RMS)." /><meta name="og:title" content="INSR-Related Severe Syndromic Insulin Resistance" /><meta name="og:type" content="book" /><meta name="og:description" content="INSR-related severe syndromic insulin resistance comprises a phenotypic spectrum that is a continuum from the severe phenotype Donohue syndrome (DS) (also known as leprechaunism) to the milder phenotype Rabson-Mendenhall syndrome (RMS)." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK476444/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/insr-ir/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK476444/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BCA23E0415601000000000934035F.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK476444_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK476444_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/image/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ipex/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK476444_"><span class="title" itemprop="name"><i>INSR</i>-Related Severe Syndromic Insulin Resistance</span></h1><p class="contrib-group"><span itemprop="author">Shani Ben Harouch</span>, MD, <span itemprop="author">Aharon Klar</span>, MD, and <span itemprop="author">Tzipora C Falik Zaccai</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK476444_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK476444_ai__"><div class="contrib half_rhythm"><span itemprop="author">Shani Ben Harouch</span>, MD<div class="affiliation small">Institute of Human Genetics<br />Galilee Medical Center<br />Nahariya, Israel</div><div class="affiliation small">Faculty of Medicine in the Galilee<br />Bar-Ilan University<br />Safed, Israel<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="li.vog.htlaeh.airahan@hcuorahneb.inahs" class="oemail">li.vog.htlaeh.airahan@hcuorahneb.inahs</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Aharon Klar</span>, MD<div class="affiliation small">Institute of Paediatric Gastroenterology and Nutrition<br />Shaare Zedek Medical Center<br />Hadassah Medical School<br />Hebrew University<br />Jerusalem, Israel<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="li.ten.retni@ralka" class="oemail">li.ten.retni@ralka</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Tzipora C Falik Zaccai</span>, MD<div class="affiliation small">Institute of Human Genetics<br />Galilee Medical Center<br />Nahariya, Israel</div><div class="affiliation small">Faculty of Medicine in the Galilee<br />Bar-Ilan University<br />Safed, Israel<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.liamg@sciteneg.dmkilaf" class="oemail">moc.liamg@sciteneg.dmkilaf</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 25, 2018</span>.</p><p><em>Estimated reading time: 25 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="insr-ir.Summary" itemprop="description"><h2 id="_insr-ir_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance comprises a phenotypic spectrum that is a continuum from the severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> Donohue syndrome (DS) (also known as leprechaunism) to the milder phenotype Rabson-Mendenhall syndrome (RMS).</p><p>DS at the severe end of the spectrum is characterized by severe insulin resistance (hyperinsulinemia with associated fasting hypoglycemia and postprandial hyperglycemia), severe prenatal growth restriction and postnatal growth failure, hypotonia and developmental delay, characteristic facies, and organomegaly involving heart, kidneys, liver, spleen, and ovaries. Death usually occurs before age one year.</p><p>RMS at the milder end of the spectrum is characterized by severe insulin resistance that, although not as severe as that of DS, is nonetheless accompanied by fluctuations in blood glucose levels, diabetic ketoacidosis, and &#x02013; in the second decade &#x02013; microvascular complications. Findings can range from severe growth delay and intellectual disability to normal growth and development. Facial features can be milder than those of DS. Complications of longstanding hyperglycemia are the most common cause of death. While death usually occurs in the second decade, some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals live longer.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with characteristic clinical findings and identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>INSR</i> pathogenic variants on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> DS: No effective treatments for insulin resistance or other manifestations of DS are currently available. Frequent feedings as well as increased protein content of evening feedings can help prevent fasting hypoglycemia.</p><p>RMS: Insulin sensitizers are used first to decrease levels of glucose and glycosylated hemoglobin (HbA1c); however, their effect diminishes with time, often requiring dose adjustments and multidrug therapy. When hyperglycemia persists, insulin is started &#x02013; usually in high doses, especially during the treatment of diabetic ketoacidosis.</p><p>Anti-androgen therapies can be used to treat hyperandrogenism. Oophorectomy may be needed.</p><p><i>Surveillance:</i> Routine monitoring of psychomotor development; glucose levels, HbA1c levels, thyroid function for evidence of hypothyroidism; cardiac status; ovarian size by ultrasound examination; urine for hypercalciuria and kidneys for nephrocalcinosis by ultrasound examination.</p><p><i>Agents/circumstances to avoid in DS:</i> Agents that cause hypoglycemia; prolonged fasting; contact with persons with contagious disease.</p><p><i>Pregnancy management:</i> Heterozygotes for an <i>INSR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are at increased risk for gestational diabetes and require monitoring for glucose intolerance before and during pregnancy. Of note, gestational diabetes, which can be hard to control, requires high doses of insulin. A high-resolution fetal ultrasound examination with fetal echocardiogram to screen for malformations is recommended; referral to a maternal-fetal medicine specialist for diabetic management during pregnancy may be considered.</p><p><i>Therapies under investigation:</i> Recombinant human IGF-1(rhIGF-1) shows promise in the treatment of severe insulin resistance; however, its benefit is not well established and it is more likely to be effective in individuals with less severe insulin resistance as the few individuals with prolonged survival with rhIGF-1 treatment had milder phenotypes. Although treatment of RMS with meterleptin (leptin replacement therapy) was beneficial to metabolic control, data to date are insufficient to support its use in patient care.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once the <i>INSR</i> pathogenic variants have been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk relatives, prenatal testing for a pregnancy at increased risk for <i>INSR</i>-related severe syndromic insulin resistance, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="insr-ir.GeneReview_Scope"><h2 id="_insr-ir_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="insr-ir.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476444/table/insr-ir.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__insr-ir.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_insr-ir.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>INSR</i>-Related Severe Syndromic Insulin Resistance: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_insr-ir.Td_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Donohue syndrome</div></li><li class="half_rhythm"><div>Rabson-Mendenhall syndrome</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#insr-ir.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="insr-ir.TF.d.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#insr-ir.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="insr-ir.Diagnosis"><h2 id="_insr-ir_Diagnosis_">Diagnosis</h2><p>No formal diagnostic criteria have been published to date for <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance, which comprises a phenotypic continuum from the severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> Donohue syndrome to the milder phenotype Rabson-Mendenhall syndrome.</p><div id="insr-ir.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance <b>should be suspected</b> in individuals with the following <a href="#insr-ir.Clinical_Findings">clinical</a>, <a href="#insr-ir.Laboratory_Findings">laboratory</a>, and <a href="#insr-ir.Imaging_Findings">imaging</a> findings of Donohue syndrome or Rabson-Mendenhall syndrome.</p><div id="insr-ir.Clinical_Findings"><h4>Clinical Findings</h4><p><b>Donohue syndrome</b> (Note: All findings are prenatal onset.)</p><ul><li class="half_rhythm"><div>Progressive intrauterine growth restriction (IUGR) from the early third trimester and postnatal failure to thrive</div></li><li class="half_rhythm"><div>Dysmorphic facial features (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F1/?report=objectonly" target="object" rid-figpopup="figinsrirF1" rid-ob="figobinsrirF1">Figure 1</a>) characterized by proptosis; infra-orbital folds; large, low-set, posteriorly rotated ears; thick vermilion of the upper and lower lips; and gingival hypertrophy [<a class="bk_pop" href="#insr-ir.REF.grasso.2013.951">Grasso et al 2013</a>]</div></li><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Developmental delay</div></li><li class="half_rhythm"><div>Other:</div><ul><li class="half_rhythm"><div>Dry skin and reduced subcutaneous fat</div></li><li class="half_rhythm"><div>Hypertrichosis (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F2/?report=objectonly" target="object" rid-figpopup="figinsrirF2" rid-ob="figobinsrirF2">Figure 2</a>)</div></li><li class="half_rhythm"><div>Acanthosis nigricans (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F2/?report=objectonly" target="object" rid-figpopup="figinsrirF2" rid-ob="figobinsrirF2">Figure 2</a>)</div></li><li class="half_rhythm"><div>Prominent nipples (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F3/?report=objectonly" target="object" rid-figpopup="figinsrirF3" rid-ob="figobinsrirF3">Figure 3</a>)</div></li><li class="half_rhythm"><div>Abdominal distention (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F4/?report=objectonly" target="object" rid-figpopup="figinsrirF4" rid-ob="figobinsrirF4">Figure 4</a>)</div></li><li class="half_rhythm"><div>Organomegaly</div></li><li class="half_rhythm"><div>Genital enlargement (males and females) (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F4/?report=objectonly" target="object" rid-figpopup="figinsrirF4" rid-ob="figobinsrirF4">Figure 4B</a>)</div></li><li class="half_rhythm"><div>Rectal hypertrophy and prolapse (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F5/?report=objectonly" target="object" rid-figpopup="figinsrirF5" rid-ob="figobinsrirF5">Figure 5</a>)</div></li></ul></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figinsrirF1" co-legend-rid="figlgndinsrirF1"><a href="/books/NBK476444/figure/insr-ir.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figinsrirF1" rid-ob="figobinsrirF1"><img class="small-thumb" src="/books/NBK476444/bin/insr-ir-Image001.gif" src-large="/books/NBK476444/bin/insr-ir-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndinsrirF1"><h4 id="insr-ir.F1"><a href="/books/NBK476444/figure/insr-ir.F1/?report=objectonly" target="object" rid-ob="figobinsrirF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Characteristic dysmorphism seen in neonate with DS: gingival overgrowth; large, low-set, posteriorly rotated ears; infraorbital folds; proptosis; thick vermilion of the upper and lower lips Figures 1A and 1C from Falik Zaccai et al [2014]</p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figinsrirF2" co-legend-rid="figlgndinsrirF2"><a href="/books/NBK476444/figure/insr-ir.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figinsrirF2" rid-ob="figobinsrirF2"><img class="small-thumb" src="/books/NBK476444/bin/insr-ir-Image002.gif" src-large="/books/NBK476444/bin/insr-ir-Image002.jpg" alt="Figure 2. . Hypertrichosis is a feature in all individuals with DS." /></a><div class="icnblk_cntnt" id="figlgndinsrirF2"><h4 id="insr-ir.F2"><a href="/books/NBK476444/figure/insr-ir.F2/?report=objectonly" target="object" rid-ob="figobinsrirF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Hypertrichosis is a feature in all individuals with DS. From Falik Zaccai et al [2014]</p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figinsrirF3" co-legend-rid="figlgndinsrirF3"><a href="/books/NBK476444/figure/insr-ir.F3/?report=objectonly" target="object" title="Figure 3. " class="img_link icnblk_img figpopup" rid-figpopup="figinsrirF3" rid-ob="figobinsrirF3"><img class="small-thumb" src="/books/NBK476444/bin/insr-ir-Image003.gif" src-large="/books/NBK476444/bin/insr-ir-Image003.jpg" alt="Figure 3. . Prominent nipples are a typical finding in neonates." /></a><div class="icnblk_cntnt" id="figlgndinsrirF3"><h4 id="insr-ir.F3"><a href="/books/NBK476444/figure/insr-ir.F3/?report=objectonly" target="object" rid-ob="figobinsrirF3">Figure 3. </a></h4><p class="float-caption no_bottom_margin">Prominent nipples are a typical finding in neonates. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figinsrirF4" co-legend-rid="figlgndinsrirF4"><a href="/books/NBK476444/figure/insr-ir.F4/?report=objectonly" target="object" title="Figure 4" class="img_link icnblk_img figpopup" rid-figpopup="figinsrirF4" rid-ob="figobinsrirF4"><img class="small-thumb" src="/books/NBK476444/bin/insr-ir-Image004.gif" src-large="/books/NBK476444/bin/insr-ir-Image004.jpg" alt="Figure 4. A and B." /></a><div class="icnblk_cntnt" id="figlgndinsrirF4"><h4 id="insr-ir.F4"><a href="/books/NBK476444/figure/insr-ir.F4/?report=objectonly" target="object" rid-ob="figobinsrirF4">Figure 4</a></h4><p class="float-caption no_bottom_margin">A and B. Abdominal distention B. Labial hypertrophy and clitorimegaly in a girl age four months with DS</p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figinsrirF5" co-legend-rid="figlgndinsrirF5"><a href="/books/NBK476444/figure/insr-ir.F5/?report=objectonly" target="object" title="Figure 5. " class="img_link icnblk_img figpopup" rid-figpopup="figinsrirF5" rid-ob="figobinsrirF5"><img class="small-thumb" src="/books/NBK476444/bin/insr-ir-Image005.gif" src-large="/books/NBK476444/bin/insr-ir-Image005.jpg" alt="Figure 5. " /></a><div class="icnblk_cntnt" id="figlgndinsrirF5"><h4 id="insr-ir.F5"><a href="/books/NBK476444/figure/insr-ir.F5/?report=objectonly" target="object" rid-ob="figobinsrirF5">Figure 5. </a></h4><p class="float-caption no_bottom_margin">Rectal hypertrophy and prolapse </p></div></div><p><b>Rabson-Mendenhall syndrome</b></p><ul><li class="half_rhythm"><div>Dysmorphic facial features that can resemble those of Donohue syndrome [<a class="bk_pop" href="#insr-ir.REF.ben_abdelaziz.2016.16">Ben Abdelaziz et al 2016</a>] or can be milder [<a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>]</div></li><li class="half_rhythm"><div>Present in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals:</div><ul><li class="half_rhythm"><div>Hypertrichosis (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F2/?report=objectonly" target="object" rid-figpopup="figinsrirF2" rid-ob="figobinsrirF2">Figure 2</a>)</div></li><li class="half_rhythm"><div>Acanthosis nigricans (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F2/?report=objectonly" target="object" rid-figpopup="figinsrirF2" rid-ob="figobinsrirF2">Figure 2</a>)</div></li><li class="half_rhythm"><div>Prominent nipples (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F3/?report=objectonly" target="object" rid-figpopup="figinsrirF3" rid-ob="figobinsrirF3">Figure 3</a>)</div></li><li class="half_rhythm"><div>Genital enlargement (males and females) (<a class="figpopup" href="/books/NBK476444/figure/insr-ir.F4/?report=objectonly" target="object" rid-figpopup="figinsrirF4" rid-ob="figobinsrirF4">Figure 4B</a>)</div></li><li class="half_rhythm"><div>Early dentition and dental crowding [<a class="bk_pop" href="#insr-ir.REF.bathi.2010.89">Bathi et al 2010</a>]</div></li></ul></li><li class="half_rhythm"><div>Growth retardation (less severe than in Donohue syndrome) [<a class="bk_pop" href="#insr-ir.REF.tuthill.2007.21">Tuthill et al 2007</a>]</div></li><li class="half_rhythm"><div>Developmental delay (variably present) [<a class="bk_pop" href="#insr-ir.REF.longo.2002.1465">Longo et al 2002</a>]</div></li></ul></div><div id="insr-ir.Laboratory_Findings"><h4>Laboratory Findings</h4><p><b>Donohue syndrome</b></p><ul><li class="half_rhythm"><div>Severe hyperinsulinemia: extremely high plasma insulin and C-peptide levels with fluctuating blood glucose levels (typically fasting hypoglycemia and postprandial hyperglycemia)</div></li><li class="half_rhythm"><div>Ketoacidosis not reported [<a class="bk_pop" href="#insr-ir.REF.ogilvystuart.2001.3319">Ogilvy-Stuart et al 2001</a>]</div></li></ul><p><b>Rabson-Mendenhall syndrome</b></p><ul><li class="half_rhythm"><div>Laboratory findings in the first year of life are the same as in Donohue syndrome.</div></li><li class="half_rhythm"><div>After age one year insulin levels decline steadily:</div><ul><li class="half_rhythm"><div>Initially resulting in increased glucose levels and fewer hypoglycemic events [<a class="bk_pop" href="#insr-ir.REF.longo.1999.2623">Longo et al 1999</a>]</div></li><li class="half_rhythm"><div>Subsequently resulting in increased risk for ketoacidosis [<a class="bk_pop" href="#insr-ir.REF.longo.1999.2623">Longo et al 1999</a>]</div></li><li class="half_rhythm"><div>Low triglyceride levels, high HDL levels [<a class="bk_pop" href="#insr-ir.REF.semple.2009.315">Semple et al 2009</a>]</div></li><li class="half_rhythm"><div>High adiponectin levels [<a class="bk_pop" href="#insr-ir.REF.semple.2008.977">Semple et al 2008</a>]</div></li></ul></li></ul></div><div id="insr-ir.Imaging_Findings"><h4>Imaging Findings</h4><p><b>Donohue syndrome and Rabson-Mendenhall syndrome</b> [<a class="bk_pop" href="#insr-ir.REF.algazali.1993.470">al-Gazali et al 1993</a>]</p><ul><li class="half_rhythm"><div>Hypertrophic cardiomyopathy</div></li><li class="half_rhythm"><div>Enlarged kidneys, liver, and spleen</div></li><li class="half_rhythm"><div>Nephrocalcinosis</div></li><li class="half_rhythm"><div>Enlarged polycystic ovaries</div></li></ul></div></div><div id="insr-ir.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the characteristic findings described above and identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>INSR</i> pathogenic variants on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK476444/table/insr-ir.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figinsrirTmoleculargenetictestingused" rid-ob="figobinsrirTmoleculargenetictestingused">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> or single-gene testing) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (genomic sequencing) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance is broad, children with the distinctive findings of Donohue syndrome described in <a href="#insr-ir.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#insr-ir.Option_1">Option 1</a>), whereas individuals with milder disease (including Rabson-Mendenhall syndrome), in which the phenotype may not be as distinctive, may be more likely to be diagnosed using genomic testing (see <a href="#insr-ir.Option_2">Option 2</a>).</p><div id="insr-ir.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance (especially Donohue syndrome), <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>INSR</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>INSR</i> and other genes of interest (see <a href="#insr-ir.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. Of note, given the rarity of <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance, some panels for diabetes mellitus may not include this gene. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK476444/table/insr-ir.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figinsrirTmoleculargenetictestingused" rid-ob="figobinsrirTmoleculargenetictestingused">Table 1</a>).</div><div class="half_rhythm">For more information on multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>.</div></li></ul></div><div id="insr-ir.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance is not as distinctive (such as milder Rabson-Mendenhall syndrome), <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>For more information on comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>.</p><div id="insr-ir.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>INSR</i>-Related Severe Syndromic Insulin Resistance</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476444/table/insr-ir.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__insr-ir.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_insr-ir.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_insr-ir.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_insr-ir.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_insr-ir.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>INSR</i></td><td headers="hd_h_insr-ir.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_insr-ir.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">58/63&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_insr-ir.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_insr-ir.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5/63&#x000a0;<sup>4</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="insr-ir.TF.1.1"><p class="no_margin">See <a href="/books/NBK476444/#insr-ir.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="insr-ir.TF.1.2"><p class="no_margin">See <a href="#insr-ir.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="insr-ir.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="insr-ir.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#insr-ir.REF.accili.1992.77s">Accili et al [1992]</a>, <a class="bk_pop" href="#insr-ir.REF.longo.2002.1465">Longo et al [2002]</a>, <a class="bk_pop" href="#insr-ir.REF.grasso.2013.951">Grasso et al [2013]</a>, <a class="bk_pop" href="#insr-ir.REF.ardon.2014.71">Ardon et al [2014]</a>, <a class="bk_pop" href="#insr-ir.REF.ben_abdelaziz.2016.16">Ben Abdelaziz et al [2016]</a></p></div></dd><dt>5. </dt><dd><div id="insr-ir.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div></div><div id="insr-ir.Clinical_Characteristics"><h2 id="_insr-ir_Clinical_Characteristics_">Clinical Characteristics</h2><div id="insr-ir.Clinical_Description"><h3>Clinical Description</h3><p><i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance comprises a phenotypic continuum from the severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> Donohue syndrome to the milder phenotype Rabson-Mendenhall syndrome. In both phenotypes, males and females are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> equally.</p><div id="insr-ir.Donohue_Syndrome"><h4>Donohue Syndrome</h4><p>Donohue syndrome (also known as leprechaunism) is characterized by severe insulin resistance manifest as hyperinsulinemia (fasting hypoglycemia and postprandial hyperglycemia), severe prenatal growth restriction and postnatal growth failure, hypotonia and developmental delay, characteristic facies, and organomegaly. Death usually occurs during the first year of life.</p><p>Birth weight and head circumference are below the third percentile. Failure to thrive is progressive; the average weight at age one year is 4-5 kg [<a class="bk_pop" href="#insr-ir.REF.longo.2002.1465">Longo et al 2002</a>].</p><p>Most infants have severe global developmental delay, including motor and cognitive impairment [<a class="bk_pop" href="#insr-ir.REF.falik_zaccai.2014.64">Falik Zaccai et al 2014</a>]. Axial hypotonia and muscle atrophy are also observed [<a class="bk_pop" href="#insr-ir.REF.baqir.2012.183">Baqir et al 2012</a>]. Intellectual disability is thought to be a consequence of recurrent, severe hypoglycemic episodes [<a class="bk_pop" href="#insr-ir.REF.ben_abdelaziz.2016.16">Ben Abdelaziz et al 2016</a>].</p><p>Reduced subcutaneous fat, hypertrichosis, and hyperkeratosis are present at birth in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants. Acanthosis nigricans can be apparent at birth or in early infancy [<a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>].</p><p>Organomegaly can include the following:</p><ul><li class="half_rhythm"><div>Hypertrophic cardiomyopathy. Present in 30% of infants, it is a major cause of death [<a class="bk_pop" href="#insr-ir.REF.geffner.1987.286">Geffner et al 1987</a>, <a class="bk_pop" href="#insr-ir.REF.hovnik.2013.1125">Hovnik et al 2013</a>, <a class="bk_pop" href="#insr-ir.REF.falik_zaccai.2014.64">Falik Zaccai et al 2014</a>].</div></li><li class="half_rhythm"><div>Enlarged kidneys. Kidney function as measured by glomerular filtration rate (GFR) and plasma creatinine concentration is normal [<a class="bk_pop" href="#insr-ir.REF.grasso.2013.951">Grasso et al 2013</a>, <a class="bk_pop" href="#insr-ir.REF.simpkin.2014.55">Simpkin et al 2014</a>].</div></li><li class="half_rhythm"><div>Hepatomegaly without liver dysfunction. Cholestasis is common in the neonatal period [<a class="bk_pop" href="#insr-ir.REF.kawashima.2013.107">Kawashima et al 2013</a>, <a class="bk_pop" href="#insr-ir.REF.hovnik.2013.1125">Hovnik et al 2013</a>].</div></li><li class="half_rhythm"><div>Rectal prolapse or hypertrophy, which sometimes requires colostomy [<a class="bk_pop" href="#insr-ir.REF.weber.2014.1237">Weber et al 2014</a>].</div></li><li class="half_rhythm"><div>Enlargement of the external genitalia in both males (enlargement of the penis) and females (labial hypertrophy and clitoral enlargement).</div></li><li class="half_rhythm"><div>Ovarian enlargement is characteristic, with multiple follicles in the ovaries. The uterus appears normal.</div></li></ul><p>Other findings that may be seen:</p><ul><li class="half_rhythm"><div>Central hypothyroidism [<a class="bk_pop" href="#insr-ir.REF.baqir.2012.183">Baqir et al 2012</a>, <a class="bk_pop" href="#insr-ir.REF.falik_zaccai.2014.64">Falik Zaccai et al 2014</a>]</div></li><li class="half_rhythm"><div>Involvement of the renin-aldosterone system, presenting with hypokalemia, hyperaldosteronism, and hyperreninemia [<a class="bk_pop" href="#insr-ir.REF.grasso.2013.951">Grasso et al 2013</a>]</div></li><li class="half_rhythm"><div>Nephrocalcinosis [<a class="bk_pop" href="#insr-ir.REF.simpkin.2014.55">Simpkin et al 2014</a>] and hypercalciuria, often seen during the first months of life and occasionally detected prenatally</div></li></ul><p>The major causes of death are complications of hypoglycemia, respiratory infections [<a class="bk_pop" href="#insr-ir.REF.elders.1982.1195">Elders et al 1982</a>, <a class="bk_pop" href="#insr-ir.REF.de_bock.2012.1416">de Bock et al 2012</a>], and cardiomyopathy [<a class="bk_pop" href="#insr-ir.REF.grasso.2013.951">Grasso et al 2013</a>].</p></div><div id="insr-ir.RabsonMendenhall_Syndrome_RMS"><h4>Rabson-Mendenhall Syndrome (RMS)</h4><p>RMS is characterized by severe insulin resistance that, although less severe than that of Donohue syndrome, is nonetheless accompanied by fluctuations in blood glucose levels, diabetic ketoacidosis, and recurrent infections [<a class="bk_pop" href="#insr-ir.REF.tuthill.2007.21">Tuthill et al 2007</a>]. Findings can range from severe growth delay and intellectual disability to normal growth and development [<a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>]. Facial features of RMS can be milder than those of Donohue syndrome (DS); advanced dentition and low hair line may be the only unusual features [<a class="bk_pop" href="#insr-ir.REF.jiang.2011.931">Jiang et al 2011</a>]. Survival in RMS can be into the third decade [<a class="bk_pop" href="#insr-ir.REF.longo.2002.1465">Longo et al 2002</a>, <a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>].</p><p>Often during the first year of life the manifestations of RMS and DS are indistinguishable; however, in other instances, the manifestations of RMS are less severe than those of DS.</p><p>Of note, children reported to have Donohue syndrome who have normal psychomotor development and survive beyond the first year of life [<a class="bk_pop" href="#insr-ir.REF.de_kerdanet.2015.331">de Kerdanet et al 2015</a>] would be considered to be on the RMS end of the spectrum of <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance.</p><p>Cutaneous changes (hirsutism), genitomegaly, and ovarian enlargement typically appear later in childhood in RMS than in DS.</p><p>Morbidity in older individuals with RMS results from prolonged hyperglycemia and hyperinsulinemia, causing early microvascular complications including proliferative retinopathy, peripheral neuropathy, renal vascular complications, and diabetic ketoacidosis [<a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>, <a class="bk_pop" href="#insr-ir.REF.carrasco_de_la_fuente.2010.e17">Carrasco de la Fuente et al 2010</a>, <a class="bk_pop" href="#insr-ir.REF.jiang.2011.931">Jiang et al 2011</a>]. These complications are also the major causes of death, usually during the second decade of life [<a class="bk_pop" href="#insr-ir.REF.semple.2010.286">Semple et al 2010</a>].</p><p>Malignancy, a rare complication of <i>INSR-</i>related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance, has been reported.</p><ul><li class="half_rhythm"><div>Endometrial carcinoma was reported in a woman age 24 years treated with rhIGF-1 for severe insulin resistance (called Donohue syndrome by the authors, but clinically more likely RMS) [<a class="bk_pop" href="#insr-ir.REF.jo.2013.33">Jo et al 2013</a>].</div></li><li class="half_rhythm"><div>Granulosa cell tumor of the ovary was reported in a girl age 35 months with severe insulin resistance treated with rhIGF-1 for 16 months [<a class="bk_pop" href="#insr-ir.REF.weber.2014.1237">Weber et al 2014</a>], and in a young girl who was untreated [<a class="bk_pop" href="#insr-ir.REF.brisigotti.1993.549">Brisigotti et al 1993</a>].</div></li></ul><p>Because two of these individuals were treated with rhIGF-1, it is possible (though as-yet unconfirmed) that the tumors resulted from an adverse effect of this treatment.</p></div></div><div id="insr-ir.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>There are no known <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> in <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance.</p></div><div id="insr-ir.Nomenclature"><h3>Nomenclature</h3><p>Donohue syndrome was first described by <a class="bk_pop" href="#insr-ir.REF.donohue.1954.505">Donohue and Uchida [1954]</a>.</p><p>Leprechaunism is a synonym of Donohue syndrome.</p></div><div id="insr-ir.Prevalence"><h3>Prevalence</h3><p>Donohue syndrome is extremely rare, estimated at 1:1,000,000 [<a class="bk_pop" href="#insr-ir.REF.desboismouthon.1997.657">Desbois-Mouthon et al 1997</a>].</p><p>To date 63 individuals with phenotypes of DS and RMS have been molecularly diagnosed and reported [<a class="bk_pop" href="#insr-ir.REF.ardon.2014.71">Ardon et al 2014</a>]; about ten other individuals have a clinically based diagnosis.</p></div></div><div id="insr-ir.Genetically_Related_Allelic_Diso"><h2 id="_insr-ir_Genetically_Related_Allelic_Diso_">Genetically Related (Allelic) Disorders</h2><p>The one other <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> known to be associated with <i>INSR</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants is <b>diabetes mellitus, insulin-resistant, with acanthosis nigricans</b> (OMIM <a href="https://omim.org/entry/610549" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610549</a>), also known as type A insulin resistance. The disorder is characterized by hyperandrogenism (manifest as hirsutism, acne, and amenorrhea) and signs of insulin resistance (e.g., acanthosis nigricans and diabetes) without obesity.</p><p>This disorder most commonly comes to attention around the time of puberty due to findings that resemble polycystic ovarian syndrome; of note, males can also be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p>The insulin resistance, which is milder than that of <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance, can be treated. Growth and cognitive abilities are normal [<a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>, <a class="bk_pop" href="#insr-ir.REF.semple.2010.286">Semple et al 2010</a>]. Mode of inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> in most cases, but <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance has been reported.</p></div><div id="insr-ir.Differential_Diagnosis"><h2 id="_insr-ir_Differential_Diagnosis_">Differential Diagnosis</h2><p>The differential diagnosis of <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance includes many rare disorders with hirsutism, severe growth failure, and developmental delay with other syndromic features, some of which are summarized in <a class="figpopup" href="/books/NBK476444/table/insr-ir.T.disorders_to_consider_in_the_d/?report=objectonly" target="object" rid-figpopup="figinsrirTdisorderstoconsiderinthed" rid-ob="figobinsrirTdisorderstoconsiderinthed">Table 2</a>.</p><div id="insr-ir.T.disorders_to_consider_in_the_d" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of <i>INSR</i>-Related Severe Syndromic Insulin Resistance</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476444/table/insr-ir.T.disorders_to_consider_in_the_d/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__insr-ir.T.disorders_to_consider_in_the_d_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th rowspan="2" scope="col" colspan="1" style="text-align:left;vertical-align:middle;">Differential<br />Diagnosis<br />Disorder</th><th rowspan="2" scope="col" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s)</th><th rowspan="2" scope="col" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th colspan="3" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of the Differential Diagnosis</th></tr><tr><th colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping</th><th colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Distinguishing</th></tr></thead><tbody><tr><td colspan="6" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Syndromes of <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> hyperinsulinemia</b></td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/bscl/">Berardinelli-Seip congenital lipodystrophy</a> (BSCL)</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>AGPAT2</i><br /><i>BSCL2</i><br /><i>PTRF</i></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Insulin resistance&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>Hepatomegaly (due to hepatic steatosis &#x00026; skeletal muscle hypertrophy in BSCL)</div></li><li class="half_rhythm"><div>Hypertrophic cardiomyopathy&#x000a0;<sup>2</sup></div></li></ul>
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Dysmorphic features (due to absence of subcutaneous fat) in BSCL unlike those in DS/RMS</div></li><li class="half_rhythm"><div>Hyperlipidemia &#x00026; liver steatosis in BSCL</div></li></ul>
</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hi/">Familial hyperinsulinism</a> (FHI)</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ABCC8</i><br /><i>GCK</i><br /><i>GLUD1</i><br /><i>HADH</i><br /><i>HNF4A</i><br /><i>KCNJ11</i><br /><i>UCP2</i></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypoglycemia (ranging from severe neonatal-onset disease to childhood-onset disease w/mild symptoms in FHI)&#x000a0;<sup>3</sup></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Dysmorphism &#x00026; failure to thrive not characteristic of FHI</div></li><li class="half_rhythm"><div>Insulin levels usually much higher in DS/RMS</div></li></ul>
</td></tr><tr><td colspan="6" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Syndromes of intrauterine growth restriction</b></td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Resistance to insulin-like growth factor 1 (OMIM <a href="http://omim.org/entry/270450" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">270450</a>)</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>IGF1R</i></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />AD</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Pre- &#x00026; postnatal growth retardation</div></li><li class="half_rhythm"><div>Mildly impaired glucose tolerance&#x000a0;<sup>4</sup></div></li><li class="half_rhythm"><div>Delayed psychomotor development</div></li><li class="half_rhythm"><div>Mild <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features</div></li></ul>
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>No hyperinsulinemia</div></li><li class="half_rhythm"><div>Only mildly impaired glucose tolerance</div></li></ul>
</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/rss/">Silver-Russell syndrome</a> (SRS)</td><td colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">See footnote 5</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>IUGR accompanied by postnatal growth deficiency&#x000a0;<sup>6</sup></div></li><li class="half_rhythm"><div>&#x02191; risk for hypoglycemia</div></li></ul>
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Dysmorphic features (limb, body, &#x00026;/or facial asymmetry) unlike those in DS/RMS</div></li><li class="half_rhythm"><div>Hypoglycemia assoc w/fasting only</div></li><li class="half_rhythm"><div>Hyperinsulinemia not a feature</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; IUGR = intrauterine growth restriction; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt>1. </dt><dd><div id="insr-ir.TF.2.1"><p class="no_margin"><a href="/books/n/gene/bscl/"><b>BSCL</b></a><b>.</b> Approximately 25%-35% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop diabetes mellitus between ages 15 and 20 years.</p></div></dd><dt>2. </dt><dd><div id="insr-ir.TF.2.2"><p class="no_margin"><a href="/books/n/gene/bscl/"><b>BSCL</b></a><b>.</b> Hypertrophic cardiomyopathy is reported in 20%-25% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div></dd><dt>3. </dt><dd><div id="insr-ir.TF.2.3"><p class="no_margin"><a href="/books/n/gene/hi/"><b>FHI</b></a> is characterized by hypoglycemia that ranges from difficult-to-manage severe neonatal-onset disease to childhood-onset disease with mild symptoms and difficult-to-diagnose hypoglycemia. Neonatal-onset disease manifests within hours to two days after birth. In the newborn period, presenting symptoms (including seizures, hypotonia, poor feeding, and apnea) may be nonspecific. In severe cases, serum glucose concentrations are typically extremely low and thus easily recognized. Childhood-onset disease manifests during the first months or years of life, and in milder cases, variable and mild hypoglycemia may make it more difficult to establish the diagnosis.</p></div></dd><dt>4. </dt><dd><div id="insr-ir.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#insr-ir.REF.klammt.2011.191">Klammt et al [2011]</a></p></div></dd><dt>5. </dt><dd><div id="insr-ir.TF.2.5"><p class="no_margin"><a href="/books/n/gene/rss/"><b>SRS</b></a> has multiple etiologies including: epigenetic changes that modify expression of genes in the <a class="def" href="/books/n/gene/glossary/def-item/imprinted/">imprinted</a> region of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 11p15.5, maternal <a class="def" href="/books/n/gene/glossary/def-item/uniparental-disomy/">uniparental disomy</a> 7, and (infrequently) AD or AR inheritance.</p></div></dd><dt>6. </dt><dd><div id="insr-ir.TF.2.6"><p class="no_margin"><a href="/books/n/gene/rss/"><b>SRS</b></a><b>.</b> The birth weight of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants is typically &#x02265;2 SD below the mean, and postnatal growth &#x02265;2 SD below the mean for length or height.</p></div></dd></dl></div></div></div></div><div id="insr-ir.Management"><h2 id="_insr-ir_Management_">Management</h2><div id="insr-ir.Evaluations_Following_Initial_Di"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of the disease and the needs in an individual diagnosed with <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance, the following (if not performed as part of the evaluation that led to diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Assessment by pediatric endocrinologist including frequent blood glucose monitoring (during fasting and after feeding) or continuous glucose monitoring; measurement of insulin levels and C-peptide; thyroid function tests</div></li><li class="half_rhythm"><div>Assessment by a nutritionist regarding feeding and diet required to achieve normal glucose levels and optimal growth</div></li><li class="half_rhythm"><div>Developmental assessment</div></li><li class="half_rhythm"><div>Evaluation by a pediatric cardiologist including echocardiography for evidence of hypertrophic cardiomyopathy</div></li><li class="half_rhythm"><div>Evaluation by a pediatric nephrologist including assessment of renal function, measurement of serum electrolytes, measurement of 24-hour urinary excretion of calcium</div></li><li class="half_rhythm"><div>Evaluation of the liver by pediatric gastroenterologist including liver function tests</div></li><li class="half_rhythm"><div>Ultrasound examination of the ovaries (in females), kidneys, liver, and spleen</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist</div></li></ul></div><div id="insr-ir.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="insr-ir.Insulin_Resistance_and_Hyperglyc"><h4>Insulin Resistance and Hyperglycemia</h4><p><b>Donohue syndrome.</b> There are currently no effective treatments for the insulin resistance or other manifestations of DS. Postprandial hyperglycemia does not respond to insulin treatment [<a class="bk_pop" href="#insr-ir.REF.semple.2010.286">Semple et al 2010</a>] or glucose-lowering therapies such as metformin [<a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>].</p><p>Frequent feedings (e.g., breastfeeding, nasogastric tube, and/or intravenous glucose) are used to prevent hypoglycemia [<a class="bk_pop" href="#insr-ir.REF.semple.2010.286">Semple et al 2010</a>].</p><p><b>Rabson-Mendenhall syndrome.</b> The first line of therapy is insulin sensitizers, which decrease the levels of glucose and glycosylated hemoglobin (HbA1c) [<a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>, <a class="bk_pop" href="#insr-ir.REF.moreira.2010.2454">Moreira et al 2010</a>]. The effect of these drugs diminishes over time, often requiring dose adjustments and multidrug therapy [<a class="bk_pop" href="#insr-ir.REF.carrasco_de_la_fuente.2010.e17">Carrasco de la Fuente et al 2010</a>].</p><p>When hyperglycemia persists, insulin is started, usually in high doses [<a class="bk_pop" href="#insr-ir.REF.chong.2013.7">Chong et al 2013</a>]. When doses greater than 200 units per day are required, the U500 concentration of soluble human insulin is recommended as part of a multiple-injection regime. In many cases, this is well tolerated and permits large incremental increases in dose without excessive discomfort. U500 can also be administrated continuously by subcutaneous insulin pump [<a class="bk_pop" href="#insr-ir.REF.semple.2010.286">Semple et al 2010</a>].</p><p>Although diabetic ketoacidosis is a major cause of morbidity and mortality in RMA, only a few reports have documented its treatment in individual patients. In these instances very high doses of insulin (&#x02264;500 U/hr) were required [<a class="bk_pop" href="#insr-ir.REF.chong.2013.7">Chong et al 2013</a>, <a class="bk_pop" href="#insr-ir.REF.moore.2017.468">Moore et al 2017</a>].</p></div><div id="insr-ir.Other_Treatments_for_Both_DS_and"><h4>Other Treatments for Both DS and RMS</h4><p><b>Cardiomyopathy.</b> Treat with beta blockers.</p><p><b>Hyperandrogenism</b></p><ul><li class="half_rhythm"><div>Treat with oral contraceptives and anti-androgens such as flutamide and spironolactone as well as finasteride, a 5a-reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone [<a class="bk_pop" href="#insr-ir.REF.bathi.2010.89">Bathi et al 2010</a>, <a class="bk_pop" href="#insr-ir.REF.wei.2017.835">Wei &#x00026; Burren 2017</a>].</div></li><li class="half_rhythm"><div>Use of a GnRH agonist to suppress gonadotrophins is also likely to be beneficial [<a class="bk_pop" href="#insr-ir.REF.brown.2017.1789">Brown et al 2017</a>].</div></li><li class="half_rhythm"><div>In some cases, removal of the ovaries is necessary to control hyperandrogenism [<a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>].</div></li></ul><p><b>Short stature.</b> Growth does not improve with human growth hormone treatment even when the child's growth hormone levels are low [<a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>, <a class="bk_pop" href="#insr-ir.REF.kim.2012.565">Kim et al 2012</a>, <a class="bk_pop" href="#insr-ir.REF.brown.2013.e1749">Brown et al 2013</a>].</p><p><b>Gonadectomy</b> may be considered when enlarged ovaries cause respiratory distress or interfere with development, and/or imaging suggests granulosa cell tumor.</p><p><b>Other</b></p><ul><li class="half_rhythm"><div>Treatment of hypothyroidism as per routine</div></li><li class="half_rhythm"><div>Rigorous workup and treatment of intercurrent infections</div></li><li class="half_rhythm"><div>Psychosocial support and guidance for the families</div></li></ul></div></div><div id="insr-ir.Surveillance_of_DS_and_RMS"><h3>Surveillance of DS and RMS</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Close supervision by a pediatrician</div></li><li class="half_rhythm"><div>Evaluation of psychomotor development every three months</div></li><li class="half_rhythm"><div>Monitoring of:</div><ul><li class="half_rhythm"><div>Capillary glucose levels before every feeding or when clinically indicated</div></li><li class="half_rhythm"><div>HbA1c levels for the evaluation of glycemic control, every three months</div></li><li class="half_rhythm"><div>Thyroid function every six months</div></li><li class="half_rhythm"><div>Cardiac status every three months</div></li><li class="half_rhythm"><div>Ovarian size every three months until age two years, then every six months</div></li><li class="half_rhythm"><div>Urine for hypercalciuria</div></li><li class="half_rhythm"><div>Kidneys for nephrocalcinosis by ultrasound examination every six months</div></li></ul></li></ul><ul><li class="half_rhythm"><div>Gynecologic evaluation when there is an abnormal vaginal bleeding, which could be a manifestation of endometrial cancer</div></li></ul></div><div id="insr-ir.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>In DS:</p><ul><li class="half_rhythm"><div>Agents that cause hypoglycemia</div></li><li class="half_rhythm"><div>Prolonged fasting</div></li><li class="half_rhythm"><div>Contact with persons with a contagious disease</div></li></ul><p>In RMS:</p><ul><li class="half_rhythm"><div>Agents that cause hyperglycemia</div></li><li class="half_rhythm"><div>High-carbohydrate diet</div></li><li class="half_rhythm"><div>Contact with persons with a contagious disease</div></li></ul></div><div id="insr-ir.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#insr-ir.Related_Genetic_Counseling_Issue">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="insr-ir.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Heterozygotes for an <i>INSR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are at increased risk for gestational diabetes and require monitoring for glucose intolerance before and during pregnancy [<a class="bk_pop" href="#insr-ir.REF.kleijer.2006.980">Kleijer et al 2006</a>].</p><p>Gestational diabetes, which can be difficult to control, requires high doses of insulin. Adding metformin can lower insulin requirements [<a class="bk_pop" href="#insr-ir.REF.enkhtuvshin.2015.e16">Enkhtuvshin et al 2015</a>].</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/background-risk/">background risk</a> for birth defects in the general population is approximately 3%-4%. Women who have pre-pregnancy insulin-dependent diabetes are at increased (i.e., ~6%-8%) risk of having a child with a birth defect. Women who develop gestational diabetes during pregnancy may be at increased risk of having a child with a birth defect compared to the background risk, but the risk appears to be less than that for women who have pre-pregnancy insulin-dependent diabetes. Appropriate glycemic control during pregnancy does not eliminate but may reduce the risk of having a child with a birth defect, and may also decrease the risk of having a child with neonatal diabetes-related complications (e.g., macrosomia, hypoglycemia, and electrolyte abnormalities).</p><p>Insulin is the preferred medication for treating women with pre-pregnancy diabetes. There are limited data on the fetal effects of metformin exposure during human pregnancy, although such data have been reassuring. Given the risks to the fetus associated with diabetes during pregnancy, aggressive treatment of chronic maternal hyperglycemia is recommended.</p><p>To screen for fetal birth defects in pregnant women with diabetes, prenatal high-resolution ultrasound with fetal echocardiogram is recommended; referral to a maternal-fetal medicine specialist may also be considered.</p><p>See <a href="http://www.mothertobaby.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mothertobaby.org</a> for more information on the use of medications during pregnancy.</p></div><div id="insr-ir.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>There are no controlled trials of any sort in <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance; thus, the two therapies discussed in this section are based on clinical experience, case series, and expert opinion.</p><div id="insr-ir.Recombinant_Human_IGF1_rhIGF1"><h4>Recombinant Human IGF-1 (rhIGF-1)</h4><p>The rationale for using rhIGF-1 to treat severe insulin resistance syndromes is based on observations of its direct effects on carbohydrate metabolism. In humans, infusion of rhIGF-1 suppresses hepatic glucose production, stimulates peripheral glucose uptake in muscle, and &#x02013; despite a significant reduction in circulating insulin levels &#x02013; causes hypoglycemia. The insulin-like growth factor 1 receptor (IGF1R) and the insulin receptor (INSR) share 60% homology and very similar intracellular activity [<a class="bk_pop" href="#insr-ir.REF.weber.2014.1237">Weber et al 2014</a>].</p><p><b>Treatment regimen.</b> Although many case reports of severe insulin resistance syndromes describe treatment with rhIGF-1, there is no standard protocol regarding this treatment. In fact, the treatment regimens either differed [<a class="bk_pop" href="#insr-ir.REF.mcdonald.2007.s51">McDonald et al 2007</a>, <a class="bk_pop" href="#insr-ir.REF.de_kerdanet.2015.331">de Kerdanet et al 2015</a>] or were not reported.</p><p>Three treatment regimens for rhIGF-1 therapy in children with severe insulin resistance were reported: subcutaneous injections two to four times a day, continuous subcutaneous infusion via insulin pump, and intravenous infusion [<a class="bk_pop" href="#insr-ir.REF.backeljauw.1994.749">Backeljauw et al 1994</a>]. Anecdotal experience suggests that the use of continuous rhIGF-1 infusion is more beneficial than divided doses. Doses ranged from 80 to 1120 &#x000b5;g/kg/day [<a class="bk_pop" href="#insr-ir.REF.mcdonald.2007.s51">McDonald et al 2007</a>].</p><p><b>Outcome of treatment.</b> In most treated children:</p><ul><li class="half_rhythm"><div>The metabolic state improved and levels of glucose, insulin, and glycosylated hemoglobin decreased.</div></li><li class="half_rhythm"><div>Growth parameters improved [<a class="bk_pop" href="#insr-ir.REF.nakae.1998.542">Nakae et al 1998</a>].</div></li><li class="half_rhythm"><div>Renal tubular dysfunction improved [<a class="bk_pop" href="#insr-ir.REF.hovnik.2013.1125">Hovnik et al 2013</a>].</div></li></ul><p>In some children treated with rhIGF-1, the degree of cardiomyopathy improved and survival was prolonged [<a class="bk_pop" href="#insr-ir.REF.mcdonald.2007.s51">McDonald et al 2007</a>, <a class="bk_pop" href="#insr-ir.REF.de_kerdanet.2015.331">de Kerdanet et al 2015</a>, <a class="bk_pop" href="#insr-ir.REF.carmody.2016.e8">Carmody et al 2016</a>], whereas in others no improvement was observed [<a class="bk_pop" href="#insr-ir.REF.musso.2004.209">Musso et al 2004</a>, <a class="bk_pop" href="#insr-ir.REF.grasso.2013.951">Grasso et al 2013</a>].</p><p><b>Potential side effects</b> include severe hypoglycemia and soft-tissue overgrowth.</p><p>Given a lack of evidence it is unclear whether the following two instances were side effects of the treatment or the hyperinsulinemia itself:</p><ul><li class="half_rhythm"><div>Endometrial carcinoma in a woman age 24 years treated with rhIGF-1 for severe insulin resistance (called Donohue syndrome by the authors, but clinically more likely RMS) [<a class="bk_pop" href="#insr-ir.REF.jo.2013.33">Jo et al 2013</a>]</div></li><li class="half_rhythm"><div>Granulosa cell tumor of the ovary in a girl age 35 months with severe insulin resistance treated with rhIGF-1 for 16 months [<a class="bk_pop" href="#insr-ir.REF.weber.2014.1237">Weber et al 2014</a>]</div></li></ul><p>To summarize the experience with rhIGF-1 treatment in severe insulin resistance syndromes: (1) its benefit is not well established; and (2) it is more likely to be effective in individuals with less severe insulin resistance, as the few individuals with prolonged survival with rhIGF-1 treatment had milder phenotypes [<a class="bk_pop" href="#insr-ir.REF.carmody.2016.e8">Carmody et al 2016</a>]. To date, rhIGF-1 appears to be the best treatment option; it is thus reasonable to consider in any patient with severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance.</p></div><div id="insr-ir.Metreleptin_Recombinant_Human_Le"><h4>Metreleptin (Recombinant Human Leptin)</h4><p>Metreleptin is approved by the FDA for treatment of <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> or acquired generalized lipodystrophy.</p><p>Leptin replacement normalized blood lipids (i.e., reduced triglycerides and increased HDL) and reduced insulin and glucose levels in syndromes with leptin deficiency. Syndromes with leptin deficiency are characterized by insulin resistance, hyperglycemia, dyslipidemia, endocrine disruptions, and fatty liver disease [<a class="bk_pop" href="#insr-ir.REF.pazfilho.2015.146">Paz-Filho et al 2015</a>] and include lipodystrophy syndromes, hypothalamic amenorrhea, anorexia nervosa, and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> leptin deficiency.</p><p>After one year of treatment with metreleptin (along with other medications including insulin, metformin, and pioglitazone), individuals with RMS showed improvement in all of the following: serum glucose levels, HbA1c levels, insulinemia, insulin dose required, caloric intake, and body fat mass [<a class="bk_pop" href="#insr-ir.REF.cochran.2004.1548">Cochran et al 2004</a>, <a class="bk_pop" href="#insr-ir.REF.brown.2013.e1749">Brown et al 2013</a>].</p><p>There are no reports of metreleptin treatment of longer duration in patients with RMS.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div></div><div id="insr-ir.Genetic_Counseling"><h2 id="_insr-ir_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="insr-ir.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="insr-ir.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are typically obligate heterozygotes (i.e., carriers of one <i>INSR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>). Note: In two reports only one parent of an affected child was <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>INSR</i> pathogenic variant, suggesting that one of the variants identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> occurred <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> [<a class="bk_pop" href="#insr-ir.REF.maassen.2003.4251">Maassen et al 2003</a>, <a class="bk_pop" href="#insr-ir.REF.kawashima.2013.107">Kawashima et al 2013</a>].</div></li><li class="half_rhythm"><div>Heterozygotes are usually asymptomatic but may have features of the allelic disorder insulin-resistant diabetes mellitus with acanthosis nigricans, especially when the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is in the intracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (see <a href="#insr-ir.Genetically_Related_Allelic_Diso">Genetically Related Disorders</a>) [<a class="bk_pop" href="#insr-ir.REF.takahashi.1997.412">Takahashi et al 1997</a>, <a class="bk_pop" href="#insr-ir.REF.longo.2002.1465">Longo et al 2002</a>, <a class="bk_pop" href="#insr-ir.REF.jiang.2011.931">Jiang et al 2011</a>].</div></li><li class="half_rhythm"><div>Note: Females who are heterozygotes for an <i>INSR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are at increased risk for gestational diabetes (see <a href="#insr-ir.Pregnancy_Management">Pregnancy Management</a>).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes are usually asymptomatic but may have features of the allelic disorder insulin-resistant diabetes mellitus with acanthosis nigricans, especially when the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is in the intracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (see <a href="#insr-ir.Genetically_Related_Allelic_Diso">Genetically Related Disorders</a>) [<a class="bk_pop" href="#insr-ir.REF.takahashi.1997.412">Takahashi et al 1997</a>, <a class="bk_pop" href="#insr-ir.REF.longo.2002.1465">Longo et al 2002</a>, <a class="bk_pop" href="#insr-ir.REF.jiang.2011.931">Jiang et al 2011</a>].</div></li><li class="half_rhythm"><div>Note: Females who are heterozygotes for an <i>INSR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are at increased risk for gestational diabetes (see <a href="#insr-ir.Pregnancy_Management">Pregnancy Management</a>).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Individuals with <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance are not known to reproduce.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>INSR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="insr-ir.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>INSR</i> pathogenic variants in the family.</p></div><div id="insr-ir.Related_Genetic_Counseling_Issue"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="insr-ir.Prenatal_Testing_and_Preimplanta"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>INSR</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="insr-ir.Resources"><h2 id="_insr-ir_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition/donohue-syndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Donohue syndrome</a></div></li><li class="half_rhythm"><div><b>National Organization for Rare Disorders (NORD)</b></div><div><a href="http://rarediseases.org/rare-diseases/leprechaunism/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Leprechaunism</a></div></li></ul></div><div id="insr-ir.Molecular_Genetics"><h2 id="_insr-ir_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="insr-ir.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>INSR-Related Severe Syndromic Insulin Resistance: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476444/table/insr-ir.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__insr-ir.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_insr-ir.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_insr-ir.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_insr-ir.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_insr-ir.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_insr-ir.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_insr-ir.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_insr-ir.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3643" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>INSR</i></a></td><td headers="hd_b_insr-ir.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3643" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19p13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_insr-ir.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P06213" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Insulin receptor</a></td><td headers="hd_b_insr-ir.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/INSR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">INSR database</a></td><td headers="hd_b_insr-ir.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=INSR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">INSR</a></td><td headers="hd_b_insr-ir.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=INSR[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">INSR</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="insr-ir.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="insr-ir.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for INSR-Related Severe Syndromic Insulin Resistance (<a href="/omim/147670,246200,262190" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476444/table/insr-ir.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__insr-ir.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/147670" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">147670</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INSULIN RECEPTOR; INSR</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/246200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">246200</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DONOHUE SYNDROME</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/262190" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">262190</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PINEAL HYPERPLASIA, INSULIN-RESISTANT DIABETES MELLITUS, AND SOMATIC ABNORMALITIES</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>INSR</i> spans more than 120 kb and has 22 exons [<a class="bk_pop" href="#insr-ir.REF.seino.1989.114">Seino et al 1989</a>]. The longest transcript (<a href="/nuccore/NM_000208.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000208.3</a>) is 9375 bp with a signal peptide sequence from nucleotides 412 to 492 and coding sequences from nucleotides 493 to 2685 (encoding the insulin receptor subunit alpha) and nucleotides 2698 to 4557 (encoding the insulin receptor subunit beta). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK476444/#insr-ir.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 70 pathogenic variants causative of <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance have been identified. They are distributed throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants as well as small deletions, insertions, and indels. Exon and multiexon deletions have been reported, including one <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of the entire gene. The latter was a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> complete <i>INSR</i> deletion observed in an infant age one year, thereby demonstrating that absence of <i>INSR</i> is compatible with life [<a class="bk_pop" href="#insr-ir.REF.wertheimer.1993.71">Wertheimer et al 1993</a>].</p><p>The prevalence of heterozygotes (carriers) for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.167T&#x0003e;C is high among Druze in Israel [<a class="bk_pop" href="#insr-ir.REF.falik_zaccai.2014.64">Falik Zaccai et al 2014</a>].</p><p>Three individuals from two unrelated families of Tunisian origin had the same novel c.3003_3012delinsGGAAG <i>INSR</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> [<a class="bk_pop" href="#insr-ir.REF.sialasahnoun.2016.165">Siala-Sahnoun et al 2016</a>].</p><div id="insr-ir.T.insr_pathogenic_variants_discu" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>INSR</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK476444/table/insr-ir.T.insr_pathogenic_variants_discu/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__insr-ir.T.insr_pathogenic_variants_discu_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_insr-ir.T.insr_pathogenic_variants_discu_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_insr-ir.T.insr_pathogenic_variants_discu_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_insr-ir.T.insr_pathogenic_variants_discu_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_insr-ir.T.insr_pathogenic_variants_discu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.167T&#x0003e;C</td><td headers="hd_h_insr-ir.T.insr_pathogenic_variants_discu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile56Thr</td><td headers="hd_h_insr-ir.T.insr_pathogenic_variants_discu_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000208.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000208<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000199.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000199<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_insr-ir.T.insr_pathogenic_variants_discu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3003_3012delinsGGAAG</td><td headers="hd_h_insr-ir.T.insr_pathogenic_variants_discu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser1001ArgfsTer37<br />(Ser1001_Asp1004delinsArgGlu)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="insr-ir.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The insulin receptor belongs to the superfamily of transmembrane receptor tyrosine kinases. The INSR preprotein, consisting of 1382 amino acids, is proteolytically processed to generate the alpha and beta subunits of INSR, a heterotetrameric glycoprotein. The 731-amino acid alpha subunit, which is external to the plasma membrane, contains the insulin-binding region. The alpha subunit is linked by disulfide bonds to the 620-amino acid beta subunit, which includes a 194-amino acid extracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, a 23-amino acid membrane-spanning segment, and a 403-amino acid cytoplasmic segment that has intrinsic tyrosine kinase activity [<a class="bk_pop" href="#insr-ir.REF.seino.1989.114">Seino et al 1989</a>].</p><p>When insulin binds to the alpha subunit, the beta subunit undergoes autophosphorylation, which activates the insulin-signaling pathway regulating glucose uptake and release as well as the synthesis and storage of carbohydrates, lipids, and protein.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<a class="bk_pop" href="#insr-ir.REF.taylor.1991.197">Taylor et al [1991]</a> described five classes of <i>INSR</i> pathogenic variants that:</p><ul><li class="half_rhythm"><div>Impair synthesis of the receptors;</div></li><li class="half_rhythm"><div>Impair transport of receptors to the cell membrane;</div></li><li class="half_rhythm"><div>Decrease receptor affinity for insulin;</div></li><li class="half_rhythm"><div>Reduce the tyrosine kinase activity of the receptor intracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>; and</div></li><li class="half_rhythm"><div>Accelerate receptor degradation [<a class="bk_pop" href="#insr-ir.REF.porter.2005.893">Porter &#x00026; Barrett 2005</a>].</div></li></ul><p>In severe insulin resistance, reduced intracellular insulin signaling causes hyperglycemia. The hypoglycemia in <i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance is thought to be a consequence of late action of IGF-1 [<a class="bk_pop" href="#insr-ir.REF.kawashima.2013.107">Kawashima et al 2013</a>]. Insulin resistance causes alternations in the expression of genes encoding growth factors and apoptosis [<a class="bk_pop" href="#insr-ir.REF.iovino.2014.4130">Iovino et al 2014</a>].</p></div><div id="insr-ir.References"><h2 id="_insr-ir_References_">References</h2><div id="insr-ir.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.accili.1992.77s">Accili D, Barbetti F, Cama A, Kadowaki H, Kadowaki T, Imano E, Levy-Toledano R, Taylor SI. Mutations in the insulin receptor gene in patients with genetic syndromes of insulin resistance and acanthosis nigricans. <span><span class="ref-journal">J Invest Dermatol. </span>1992;<span class="ref-vol">98</span>:77S–81S.</span> [<a href="/pubmed/1588128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1588128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.algazali.1993.470">al-Gazali LI, Khalil M, Devadas K. A syndrome of insulin resistance resembling leprechaunism in five sibs of consanguineous parents. <span><span class="ref-journal">J Med Genet. </span>1993;<span class="ref-vol">30</span>:470–5.</span> [<a href="/pmc/articles/PMC1016418/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1016418</span></a>] [<a href="/pubmed/8326490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8326490</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.ardon.2014.71">Ardon O, Procter M, Tvrdik T, Longo N, Mao R. Sequencing analysis of insulin receptor defects and detection of two novel mutations in INSR gene. <span><span class="ref-journal">Mol Genet Metab Rep. </span>2014;<span class="ref-vol">1</span>:71–84.</span> [<a href="/pmc/articles/PMC5121292/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5121292</span></a>] [<a href="/pubmed/27896077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27896077</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.backeljauw.1994.749">Backeljauw PF, Alves C, Eidson M. Effect of intravenous insulin-like growth factor I in two patients with leprechaunism. <span><span class="ref-journal">Pediatr Res. </span>1994;<span class="ref-vol">36</span>:749–54.</span> [<a href="/pubmed/7534902" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7534902</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.baqir.2012.183">Baqir ZS, Al-Lawati TT, Al Hussaini SO, Al-Sinani A, Al-Said K, Al-Rashdi I. A novel leprechaunism mutation, Cys807Arg, in an Arab infant: a rare cause of hypoglycaemia. <span><span class="ref-journal">Paediatr Int Child Health. </span>2012;<span class="ref-vol">32</span>:183–5.</span> [<a href="/pubmed/22824672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22824672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.bathi.2010.89">Bathi RJ, Parveen S, Mutalik S. Rabson-Mendenhall syndrome&#x0202f;: two case reports and a brief review of the literature. <span><span class="ref-journal">Odontology. </span>2010;<span class="ref-vol">98</span>:89–96.</span> [<a href="/pubmed/20155514" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20155514</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.ben_abdelaziz.2016.16">Ben Abdelaziz R, Ben Chehida A, Azzouz H, Boudabbous H, Lascols O, Ben Turkia H, Tebib N. A novel homozygous missense mutation in the insulin receptor gene results in an atypical presentation of Rabson-Mendenhall syndrome. <span><span class="ref-journal">Eur J Med Genet. </span>2016;<span class="ref-vol">59</span>:16–9.</span> [<a href="/pubmed/26691667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26691667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.brisigotti.1993.549">Brisigotti M, Fabbretti G, Pesce F, Gatti R, Cohen A, Parenti G, Callea F. Congenital bilateral juvenile granulosa cell tumor of the ovary in leprechaunism: a case report. <span><span class="ref-journal">Pediatr Pathol. </span>1993;<span class="ref-vol">13</span>:549–58.</span> [<a href="/pubmed/8247952" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8247952</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.brown.2013.e1749">Brown RJ, Cochran E, Gorden P. Metreleptin improves blood glucose in patients with insulin receptor mutations. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2013;<span class="ref-vol">98</span>:E1749–56.</span> [<a href="/pmc/articles/PMC3816267/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3816267</span></a>] [<a href="/pubmed/23969187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23969187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.brown.2017.1789">Brown RJ, Joseph J, Cochran E, Gewert C, Semple R, Gorden P. Type B insulin resistance masquerading as ovarian hyperthecosis. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2017;<span class="ref-vol">102</span>:1789–91.</span> [<a href="/pmc/articles/PMC5470776/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5470776</span></a>] [<a href="/pubmed/27911591" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27911591</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.carmody.2016.e8">Carmody D, Ladsaria SS, Buikema RK, Semple RK, Greeley SAW. Successful rhIGF1 treatment for over 5 years in a patient with severe insulin resistance due to homozygous insulin receptor mutation. <span><span class="ref-journal">Diabet Med. </span>2016;<span class="ref-vol">33</span>:e8–e12.</span> [<a href="/pmc/articles/PMC4751063/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4751063</span></a>] [<a href="/pubmed/26262567" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26262567</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.carrasco_de_la_fuente.2010.e17">Carrasco de la Fuente M, Barrio Castellanos R, Alonso Blanco M, de la Calle Blasco H. Long survival in Rabson-Mendenhall syndrome. <span><span class="ref-journal">Diabetes Res Clin Pract. </span>2010;<span class="ref-vol">89</span>:e17–18.</span> [<a href="/pubmed/20627358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20627358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.chong.2013.7">Chong YH, Taylor BJ, Wheeler BJ. Renal manifestations of severe Rabson-Mendenhall syndrome: a case report. <span><span class="ref-journal">J Diabetes Metab Disord. </span>2013;<span class="ref-vol">12</span>:7.</span> [<a href="/pmc/articles/PMC3598197/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3598197</span></a>] [<a href="/pubmed/23497647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23497647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.cochran.2004.1548">Cochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004;<span class="ref-vol">89</span>:1548–54.</span> [<a href="/pubmed/15070911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15070911</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.de_bock.2012.1416">de Bock M, Hayes I, Semple R. Donohue syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2012;<span class="ref-vol">97</span>:1416–17.</span> [<a href="/pubmed/22399506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22399506</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.de_kerdanet.2015.331">de Kerdanet M, Caron-Debarle M, Nivot S, Gaillot T, Lascols O, Fremont B, Bonnaure-Mallet M, Gie S, Massart C, Capeau J. Ten-year improvement of insulin resistance and growth with recombinant human insulin-like growth factor 1 in a patient with insulin receptor mutations resulting in leprechaunism. <span><span class="ref-journal">Diabetes Metab. </span>2015;<span class="ref-vol">41</span>:331–7.</span> [<a href="/pubmed/25465274" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25465274</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.desboismouthon.1997.657">Desbois-Mouthon C, Girodon E, Ghanem N, Caron M, Pennerath A, Conteville P, Magre J, Besmond C, Goossens M, Capeau J, Amselem S. Molecular analysis of the insulin receptor gene for prenatal diagnosis of leprechaunism in two families. <span><span class="ref-journal">Prenat Diagn. </span>1997;<span class="ref-vol">17</span>:657–63.</span> [<a href="/pubmed/9249867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9249867</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.donohue.1954.505">Donohue WL, Uchida I. Leprechaunism: a euphemism for a rare familial disorder. <span><span class="ref-journal">J Pediatr. </span>1954;<span class="ref-vol">45</span>:505–19.</span> [<a href="/pubmed/13212592" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13212592</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.elders.1982.1195">Elders MJ, Schedewie HK, Olefsky J, Givens B, Char F, Bier DM, Baldwin D, Fiser RH, Seyedabadi S, Rubenstein A. Endocrine-metabolic relationships in patients with leprechaunism. <span><span class="ref-journal">J Natl Med Assoc. </span>1982;<span class="ref-vol">74</span>:1195–210.</span> [<a href="/pmc/articles/PMC2561419/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2561419</span></a>] [<a href="/pubmed/7154104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7154104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.enkhtuvshin.2015.e16">Enkhtuvshin B, Nagashima S, Saito N, Wakabayashi T, Ando A, Takahashi M, Sakai K, Yamamuro D, Nagasaka S, Tamemoto H, Ishibashi S. Successful pregnancy outcomes in a patient with type A insulin resistance syndrome. <span><span class="ref-journal">Diabet Med. </span>2015;<span class="ref-vol">32</span>:e16–e19.</span> [<a href="/pmc/articles/PMC5034500/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5034500</span></a>] [<a href="/pubmed/25472847" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25472847</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.falik_zaccai.2014.64">Falik Zaccai TC, Kalfon L, Klar A, Elisha M, Ben, Hurvitz H, Weingarten G, Chechik E, Fleisher Sheffer V, Haj Yahya R, Meidan G, Gross-Kieselstein E, Bauman D, Hershkovitz S, Yaron Y, Orr-Urtreger A, Wertheimer E. Two novel mutations identified in familial cases with Donohue syndrome. <span><span class="ref-journal">Mol Genet Genomic Med. </span>2014;<span class="ref-vol">2</span>:64–72.</span> [<a href="/pmc/articles/PMC3907912/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3907912</span></a>] [<a href="/pubmed/24498630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24498630</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.geffner.1987.286">Geffner ME, Kaplan SA, Bersch N, Lippe BM, Smith WG, Nagel RA, Santulli TV Jr, Li CH, Golde DW. Leprechaunism: in vitro insulin action despite genetic insulin resistance. <span><span class="ref-journal">Pediatr Res. </span>1987;<span class="ref-vol">22</span>:286–91.</span> [<a href="/pubmed/3309859" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3309859</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.grasso.2013.951">Grasso V, Colombo C, Favalli V, Galderisi A, Rabbone I, Gombos S, Bonora E, Massa O, Meschi F, Cerutti F, Iafusco D, Bonfanti R, Monciotti C, Barbetti F. Six cases with severe insulin resistance (SIR) associated with mutations of insulin receptor: Is a Bartter-like syndrome a feature of congenital SIR? <span><span class="ref-journal">Acta Diabetol. </span>2013;<span class="ref-vol">50</span>:951–7.</span> [<a href="/pubmed/23824322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23824322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.hovnik.2013.1125">Hovnik T, Bratani&#x0010d; N, Podkraj&#x00161;ek KT, Kova&#x0010d; J, Paro D, Podnar T, Bratina N, Battelino T. Severe progressive obstructive cardiomyopathy and renal tubular dysfunction in Donohue syndrome with decreased insulin receptor autophosphorylation due to a novel INSR mutation. <span><span class="ref-journal">Eur J Pediatr. </span>2013;<span class="ref-vol">172</span>:1125–9.</span> [<a href="/pubmed/23229189" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23229189</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.iovino.2014.4130">Iovino S, Burkart AM, Kriauciunas K, Warren L, Hughes KJ, Molla M, Lee YK, Patti ME, Kahn CR. Genetic insulin resistance is a potent regulator of gene expression and proliferation in human iPS cells. <span><span class="ref-journal">Diabetes. </span>2014;<span class="ref-vol">63</span>:4130–42.</span> [<a href="/pmc/articles/PMC4238001/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4238001</span></a>] [<a href="/pubmed/25059784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25059784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.jiang.2011.931">Jiang S, Fang Q, Zhang F, Wan H, Zhang R, Wang C, Bao Y, Zhang L, Ma X, Lu J, Gao F, Xiang K, Jia W. Functional characterization of insulin receptor gene mutations contributing to Rabson-Mendenhall syndrome - phenotypic heterogeneity of insulin receptor gene mutations. <span><span class="ref-journal">Endocr J. </span>2011;<span class="ref-vol">58</span>:931–40.</span> [<a href="/pubmed/21869538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21869538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.jo.2013.33">Jo W, Sudo S, Nakamura A, Endo D, Konno Y, Ishizu K, Tajima T. Development of endometrial carcinoma in a patient with leprechaunism (Donohue syndrome). <span><span class="ref-journal">Clin Pediatr Endocrinol. </span>2013;<span class="ref-vol">22</span>:33–8.</span> [<a href="/pmc/articles/PMC3756185/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3756185</span></a>] [<a href="/pubmed/23990696" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23990696</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.kawashima.2013.107">Kawashima Y, Nishimura R, Utsunomiya A, Kagawa R, Funata H, Fujimoto M, Hanaki K, Kanzaki S. Leprechaunism (Donohue syndrome): a case bearing novel compound heterozygous mutations in the insulin receptor gene. <span><span class="ref-journal">Endocr J. </span>2013;<span class="ref-vol">60</span>:107–12.</span> [<a href="/pubmed/22972224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22972224</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.kim.2012.565">Kim D, Cho SY, Sohn YB, Kwon M. Two novel insulin receptor gene mutations in a patient with Rabson-Mendenhall syndrome&#x0202f;: the first Korean case confirmed by biochemical and molecular evidence. <span><span class="ref-journal">J Korean Med Sci. </span>2012;<span class="ref-vol">27</span>:565–8.</span> [<a href="/pmc/articles/PMC3342552/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3342552</span></a>] [<a href="/pubmed/22563226" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22563226</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.klammt.2011.191">Klammt J, Kiess W, Pf&#x000e4;ffle R. IGF1R mutations as cause of SGA. <span><span class="ref-journal">Best Pract Res Clin Endocrinol Metab. </span>2011;<span class="ref-vol">25</span>:191–206.</span> [<a href="/pubmed/21396585" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21396585</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.kleijer.2006.980">Kleijer WJ, van der Sterre MLT, Garritsen VH, Raams A, Jaspers NGJ. Prenatal diagnosis of the Cockayne syndrome: survey of 15 years experience. <span><span class="ref-journal">Prenat Diagn. </span>2006;<span class="ref-vol">26</span>:980–4.</span> [<a href="/pubmed/16941719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16941719</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.longo.1999.2623">Longo N, Wang Y, Pasquali M. Progressive decline in insulin levels in Rabson-Mendenhall syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1999;<span class="ref-vol">84</span>:2623–9.</span> [<a href="/pubmed/10443650" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10443650</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.longo.2002.1465">Longo N, Wang Y, Smith SA, Langley SD, DiMeglio LA, Giannella-Neto D. Genotype-phenotype correlation in inherited severe insulin resistance. <span><span class="ref-journal">Hum Mol Genet. </span>2002;<span class="ref-vol">11</span>:1465–75.</span> [<a href="/pubmed/12023989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12023989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.maassen.2003.4251">Maassen JA, Tobias ES, Kayserilli H, Tukel T, Yuksel-Apak M, D'Haens E, Kleijer WJ, F&#x000e9;ry F, van der Zon GC. Identification and functional assessment of novel and known insulin receptor mutations in five patients with syndromes of severe insulin resistance. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2003;<span class="ref-vol">88</span>:4251–7.</span> [<a href="/pubmed/12970295" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12970295</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.mcdonald.2007.s51">McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB. IGF-I treatment of insulin resistance. <span><span class="ref-journal">Eur J Endocrinol. </span>2007;<span class="ref-vol">157</span>:S51–6.</span> [<a href="/pubmed/17785698" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17785698</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.moore.2017.468">Moore MM, Bailey AM, Flannery AH, Baum RA. Treatment of diabetic ketoacidosis with intravenous U-500 insulin in a patient with Rabson-Mendenhall syndrome: a case report. <span><span class="ref-journal">J Pharm Pract. </span>2017;<span class="ref-vol">30</span>:468–75.</span> [<a href="/pubmed/27112737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27112737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.moreira.2010.2454">Moreira RO, Zagury RL, Nascimento TS. Multidrug therapy in a patient with Rabson-Mendenhall syndrome. <span><span class="ref-journal">Diabetologia. </span>2010;<span class="ref-vol">53</span>:2454–5.</span> [<a href="/pubmed/20711714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20711714</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.musso.2004.209">Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. <span><span class="ref-journal">Medicine (Baltimore). </span>2004;<span class="ref-vol">83</span>:209–22.</span> [<a href="/pubmed/15232309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15232309</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.nakae.1998.542">Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1998;<span class="ref-vol">83</span>:542–9.</span> [<a href="/pubmed/9467572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9467572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.ogilvystuart.2001.3319">Ogilvy-Stuart AL, Soos MA, Hands SJ, Anthony MY, Dunger DB, O'Rahilly S. Hypoglycemia and resistance to ketoacidosis in a subject without functional insulin receptors. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2001;<span class="ref-vol">86</span>:3319–26.</span> [<a href="/pubmed/11443207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11443207</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.pazfilho.2015.146">Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment&#x0202f;: facts and expectations. <span><span class="ref-journal">Metabolism. </span>2015;<span class="ref-vol">64</span>:146–56.</span> [<a href="/pubmed/25156686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25156686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.porter.2005.893">Porter JR, Barrett TG. Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and b cell failure. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:893–902.</span> [<a href="/pmc/articles/PMC1735963/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735963</span></a>] [<a href="/pubmed/15772126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15772126</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.sialasahnoun.2016.165">Siala-Sahnoun O, Dhieb D, Ben Thabet A, Hmida N, Belguith N, Fakhfakh F. First molecular diagnosis of Donohue syndrome in Africa: novel unusual insertion/deletion mutation in the INSR gene. <span><span class="ref-journal">Mol Biol Rep. </span>2016;<span class="ref-vol">43</span>:165–73.</span> [<a href="/pubmed/26874853" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26874853</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.seino.1989.114">Seino S, Seinot M, Nishi S, Bell GI. Structure of the human insulin receptor gene and characterization of its promoter. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1989;<span class="ref-vol">86</span>:114–8.</span> [<a href="/pmc/articles/PMC286414/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC286414</span></a>] [<a href="/pubmed/2911561" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2911561</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.semple.2008.977">Semple RK, Cochran EK, Soos MA, Burling KA, Savage DB, Gorden P, O'Rahilly S. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. <span><span class="ref-journal">Diabetes Care. </span>2008;<span class="ref-vol">31</span>:977–9.</span> [<a href="/pubmed/18299442" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18299442</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.semple.2009.315">Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, Soos MA, Carpenter TA, Lomas DJ, Cochran EK, Gorden P, O'Rahilly S, Savage DB. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. <span><span class="ref-journal">J Clin Invest. </span>2009;<span class="ref-vol">119</span>:315–22.</span> [<a href="/pmc/articles/PMC2631303/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2631303</span></a>] [<a href="/pubmed/19164855" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19164855</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.semple.2010.286">Semple RK, Williams RM, Dunger DB. What is the best management strategy for patients with severe insulin resistance? <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2010;<span class="ref-vol">73</span>:286–90.</span> [<a href="/pubmed/20455892" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20455892</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.simpkin.2014.55">Simpkin A, Cochran E, Cameron F, Dattani M, de Bock M, Dunger DB, Forsander G, Guran T, Harris J, Isaac I, Hussain K, Kleta R, Peters C, Tasic V, Williams R, Yap Kok Peng F, O'Rahilly S, Gorden P, Semple RK, Bockenhauer D. Insulin receptor and the kidney: nephrocalcinosis in patients with recessive INSR mutations. <span><span class="ref-journal">Nephron Physiol. </span>2014;<span class="ref-vol">128</span>:55–61.</span> [<a href="/pmc/articles/PMC4369119/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4369119</span></a>] [<a href="/pubmed/25358339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25358339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.takahashi.1997.412">Takahashi Y, Kadowaki H, Momomura K, Fukushima Y, Orban T, Okai T, Taketani Y, Akanuma Y, Yazaki Y, Kadowaki T. A homozygous kinase-defective mutation in the insulin receptor gene in a patient with leprechaunism. <span><span class="ref-journal">Diabetologia. </span>1997;<span class="ref-vol">40</span>:412–20.</span> [<a href="/pubmed/9112018" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9112018</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.taylor.1991.197">Taylor SI, Accili D, Cama A, Kadowaki H, Kadowaki T, Imano E, Sierra ML. Mutations in the insulin receptor gene in patients with genetic syndromes of insulin resistance. <span><span class="ref-journal">Adv Exp Med Biol. </span>1991;<span class="ref-vol">293</span>:197–213.</span> [<a href="/pubmed/1767731" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1767731</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.tuthill.2007.21">Tuthill A, Semple RK, Day R, Soos MA, Sweeney E, Seymour PJ, Didi M, O'Rahilly S. Functional characterization of a novel insulin receptor mutation contributing to Rabson-Mendenhall syndrome. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2007;<span class="ref-vol">66</span>:21–6.</span> [<a href="/pubmed/17201797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17201797</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.weber.2014.1237">Weber DR, Stanescu DE, Semple R, Holland C, Magge SN. Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome. <span><span class="ref-journal">J Pediatr Endocrinol Metab. </span>2014;<span class="ref-vol">27</span>:1237–41.</span> [<a href="/pmc/articles/PMC4535795/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4535795</span></a>] [<a href="/pubmed/25153212" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25153212</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.wei.2017.835">Wei C, Burren CP. Diagnostic and management challenges from childhood, puberty through to transition in severe insulin resistance due to insulin receptor mutations. <span><span class="ref-journal">Pediatr Diabetes. </span>2017;<span class="ref-vol">18</span>:835–8.</span> [<a href="/pubmed/28093873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28093873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="insr-ir.REF.wertheimer.1993.71">Wertheimer E, Lu S, Backeljauw P, Davenport M, Taylor S. Homozygous deletion of the human insulin receptor gene results in leprechaunism. <span><span class="ref-journal">Nat Genet. </span>1993;<span class="ref-vol">5</span>:71–3.</span> [<a href="/pubmed/7693131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7693131</span></a>]</div></li></ul></div></div><div id="insr-ir.Chapter_Notes"><h2 id="_insr-ir_Chapter_Notes_">Chapter Notes</h2><div id="insr-ir.Author_Notes"><h3>Author Notes</h3><p>Research interests:</p><ul><li class="half_rhythm"><div>Searching for genes responsible for various rare genetic disorders and investigating the clinical, biochemical, and molecular basis for each disorder by studying the related protein function and biologic pathway. Diseases currently of particular interest include neurogenetic diseases, aplasia of distal phalanges with juvenile breast hypertrophy (MDN), osteogenesis imperfecta, and hereditary spastic paraparesis and cardiomyopathies.</div></li><li class="half_rhythm"><div>Identification of new pathogenic variants, genes, and proteins involved in NER-type DNA repair mechanisms. Understanding their cellular function and their role in premature aging and cancer. In addition, the establishment of new diagnostic procedures for the screening of causative pathogenic variants in the patient population in Israel and the Middle East.</div></li><li class="half_rhythm"><div>Development of methods of <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> tailored to kindreds at high risk for genetic disorders, in an attempt to raise awareness and to prevent and minimize the births of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Also, early identification of affected newborns is critical for provision of prompt and effective treatment.</div></li><li class="half_rhythm"><div>Genetics of pain: Our interest in this field is manifested in the study of women with vulvodynia (pain during sexual intercourse). This phenomenon is evident within families, and genetic associations have been found. With the collaboration of Professor J Bornstein, we are studying possible genetic associations that relate to biochemical pathways involved in pain regulation among a large cohort of women <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with vulvodynia.</div></li></ul><p>Dr Falik Zaccai's <a href="http://medweb.md.biu.ac.il/research/tzipora-falik-zaccai/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">web page</a></p></div><div id="insr-ir.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>25 January 2018 (bp) Review posted live</div></li><li class="half_rhythm"><div>14 March 2016 (sbh) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK476444</span><span class="label">PMID: <a href="/pubmed/29369573" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">29369573</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/image/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ipex/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK476444&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK476444/?report=reader">PubReader</a></li><li><a href="/books/NBK476444/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK476444" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK476444" style="display:none" title="Cite this Page"><div class="bk_tt">Ben Harouch S, Klar A, Falik Zaccai TC. INSR-Related Severe Syndromic Insulin Resistance. 2018 Jan 25. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK476444/pdf/Bookshelf_NBK476444.pdf">PDF version of this page</a> (1.5M)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#insr-ir.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#insr-ir.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#insr-ir.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#insr-ir.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#insr-ir.Genetically_Related_Allelic_Diso" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#insr-ir.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#insr-ir.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#insr-ir.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#insr-ir.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#insr-ir.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#insr-ir.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#insr-ir.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3643[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">INSR</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4495146" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4495146" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4495146" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4495146" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21634085" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phosphorylase Kinase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phosphorylase Kinase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Herbert M, Goldstein JL, Rehder C, Austin S, Kishnani PS, Bali DS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301444" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alström Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alström Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Paisey RB, Steeds R, Barrett T, Williams D, Geberhiwot T, Gunay-Aygun M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301503" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sloan JL, Carrillo N, Adams D, Venditti CP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301603" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang D, Pascual JM, De Vivo D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31804789" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fructose-1,6-Bisphosphatase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fructose-1,6-Bisphosphatase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bijarnia-Mahay S, Bhatia S, Arora V. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=29369573" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=29369573" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04299f75f66d18aaed2881">INSR-Related Severe Syndromic Insulin Resistance - GeneReviews®</a><div class="ralinkpop offscreen_noflow">INSR-Related Severe Syndromic Insulin Resistance - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:31:43-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8BCA23E0415601000000000934035F&amp;ncbi_session=CE8BCA23E04299E1_2356SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK476444%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK476444&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK476444/&amp;ncbi_pagename=INSR-Related Severe Syndromic Insulin Resistance - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8BCA23E04299E1_2356SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>